Guselkumab market reference price and detailed description of drug purchasing channels in different regions

Guselkumab (Guselkumab) is a monoclonal antibody targeting interleukin-23 (IL-23). It is mainly used to treat patients with moderate to severe plaque psoriasis. The drug has been launched in China, providing patients with a new biological agent treatment option. Because of its clear targeted mechanism of action and its ability to significantly improve skin lesions and symptoms, it has received widespread clinical attention.

In terms of price, each box of guselkumab in the domestic market sells for about four to five thousand yuan, and the specific price will vary depending on pharmacies in different regions. Patients should confirm the latest selling price with the hospital pharmacy before purchasing to ensure that the cost budget is reasonable. The drug has been included in medical insurance, which can reduce patients' out-of-pocket burden to a certain extent.

Medical insurance reimbursement ratios vary by region. Some areas may have higher reimbursement ratios, while others may have slightly lower reimbursement ratios. Therefore, patients should consult local medical insurance policies and reimbursement procedures before using guselkumab to ensure that they can smoothly enjoy medical insurance benefits. Patients on long-term treatment especially need to pay attention to reimbursement policies to reduce financial pressure.

In addition to domestic channels, guselkumab is also sold in overseas markets, but the price is usually higher. Patients who need to purchase drugs overseas should go through formal channels and ensure that the source of the drugs is legal and reliable. Overall, guselkumab has been launched in China and is included in medical insurance, providing a safe and effective treatment option for patients with moderate to severe psoriasis. At the same time, drug purchase channels and price information are transparent, which can provide patients with a reference for drug use.

Reference materials:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680254/